ANNX

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon, Inc. (ANNX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.4
EV / EBITDA -2.7
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -32.4%
Price Return 12M 33.2%
Catalyst Signal 0.00
Market Cap $681.0M
TTM Revenue N/A
Price / Sales N/A
ROE -130.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D+ (1.7) D+ (1.6) C- (2.0) C+ (2.6) C- (2.1)
2026-11-10 C+ (2.5) D+ (1.8) D+ (1.7) C (2.2) A+ (5.0) C+ (2.6)
2026-11-03 C+ (2.5) D+ (1.7) D+ (1.7) C (2.2) A+ (5.0) C+ (2.6)
2026-10-27 C+ (2.5) D+ (1.7) D+ (1.8) D+ (1.8) A+ (5.0) C+ (2.5)
2026-10-20 C+ (2.5) D+ (1.7) D+ (1.8) C- (1.9) A+ (5.0) C+ (2.6)
Page 1 of 4